573 related articles for article (PubMed ID: 27149976)
21. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
[TBL] [Abstract][Full Text] [Related]
22. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
[TBL] [Abstract][Full Text] [Related]
23. [Second trimester maternal serum screening for Down's syndrome in mainland China: a multi-center prospective study].
Bian XM; Liu JT; Qi QW; Jiang YL; Li Y; Liu SY; Hao N; Zhou J; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Liao C; Cai Y; Wang H; Wang Z; Zhu J; Hu YL
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):805-9. PubMed ID: 19087560
[TBL] [Abstract][Full Text] [Related]
24. Antenatal reflex DNA screening for trisomy 18 and trisomy 13 in addition to Down's syndrome.
Bestwick JP; Wald NJ
J Med Screen; 2016 Dec; 23(4):171-174. PubMed ID: 26790709
[TBL] [Abstract][Full Text] [Related]
25. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
[TBL] [Abstract][Full Text] [Related]
26. Prospective assessment of the Hong Kong Hospital Authority universal Down syndrome screening programme.
Sahota DS; Leung WC; Chan WP; To WW; Lau ET; Leung TY
Hong Kong Med J; 2013 Apr; 19(2):101-8. PubMed ID: 23535668
[TBL] [Abstract][Full Text] [Related]
27. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
[TBL] [Abstract][Full Text] [Related]
28. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
[TBL] [Abstract][Full Text] [Related]
29. [Clinical effect of expanded non-invasive prenatal testing for serological screening of fetuses with high-risk for Down's syndrome].
Dai P; Kong X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):1012-1016. PubMed ID: 34625944
[TBL] [Abstract][Full Text] [Related]
30. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
[TBL] [Abstract][Full Text] [Related]
31. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
32. The future of prenatal diagnosis: rapid testing or full karyotype? An audit of chromosome abnormalities and pregnancy outcomes for women referred for Down's Syndrome testing.
Ogilvie CM; Lashwood A; Chitty L; Waters JJ; Scriven PN; Flinter F
BJOG; 2005 Oct; 112(10):1369-75. PubMed ID: 16167939
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy].
Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM
Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832
[TBL] [Abstract][Full Text] [Related]
34. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study.
Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y
Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411
[TBL] [Abstract][Full Text] [Related]
35. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
36. No. 261-Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies.
Chitayat D; Langlois S; Wilson RD
J Obstet Gynaecol Can; 2017 Sep; 39(9):e380-e394. PubMed ID: 28859781
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating non-invasive prenatal testing.
Maxwell S; O'Leary P; Dickinson JE; Suthers GK
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):432-439. PubMed ID: 28369759
[TBL] [Abstract][Full Text] [Related]
38. Fewer women aged 35 and older choose serum screening for Down's syndrome: Impact and implications.
Lambert-Messerlian G; Palomaki GE
J Med Screen; 2019 Jun; 26(2):59-66. PubMed ID: 30253677
[TBL] [Abstract][Full Text] [Related]
39. Introduction of first trimester combined test increases uptake of Down's syndrome screening.
Tringham GM; Nawaz TS; Holding S; Mcfarlane J; Lindow SW
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):95-8. PubMed ID: 21839574
[TBL] [Abstract][Full Text] [Related]
40. Second tier non-invasive prenatal testing in a regional prenatal diagnosis service unit: a retrospective analysis and literature review.
Ng VKS; Chan AL; Lau WL; Leung WC
Hong Kong Med J; 2020 Feb; 26(1):10-18. PubMed ID: 32051331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
